MicroRNA-31 initiates lung tumorigenesis and promotes mutant KRAS-driven lung cancer

Journal of Clinical Investigation

Volumn 126, Issue 1, 2016, Pages 349-364

  Edmonds, Mick D ^a   Boyd, Kelli L ^a   Moyo, Tamara ^a   Mitra, Ramkrishna ^a   Duszynski, Robert ^a   Arrate, Maria Pia ^a   Chen, Xi ^b   Zhao, Zhongming ^a   Blackwell, Timothy S ^a   Andl, Thomas ^a   Eischen, Christine M ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

K RAS PROTEIN; MICRORNA 31; MITOGEN ACTIVATED PROTEIN KINASE; KRAS PROTEIN, HUMAN; MICRORNA; MIRN31 MICRORNA, HUMAN; PROTEIN P21; RAS PROTEIN;

ANIMAL MODEL; ARTICLE; CANCER SURVIVAL; CARCINOGENESIS; CELL GROWTH; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; EPITHELIUM CELL; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HYPERPLASIA; LUNG ADENOCARCINOMA; LUNG ADENOMA; LUNG ALVEOLUS EPITHELIUM; LUNG HYPERPLASIA; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; ADENOCARCINOMA; ANIMAL; FEMALE; GENETICS; LUNG NEOPLASMS; MALE; MORTALITY; MUTATION; NIH 3T3 CELL LINE; PHYSIOLOGY; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; CELL LINE, TUMOR; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICRORNAS; MUTATION; NIH 3T3 CELLS; PROTO-ONCOGENE PROTEINS P21(RAS); RAS PROTEINS;

EID: 84956638560     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI82720     Document Type: Article

References (52)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5-29.
2. Vidigal JA, Ventura A. The biological functions of miRNAs: lessons from in vivo studies. Trends Cell Biol. 2015;25(3):137-147.
3. Costinean S, et al. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci U S A. 2006;103(18):7024-7029.
4. Medina PP, Nolde M, Slack FJ. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature. 2010;467(7311):86-90.
5. Sandhu SK, et al. B-cell malignancies in microRNA Emu-miR-17~92 transgenic mice. Proc Natl Acad Sci U S A. 2013;110(45):18208-18213.
6. Hatley ME, et al. Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21. Cancer Cell. 2010;18(3):282-293.
7. Riely GJ, Marks J, Pao W. KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc. 2009;6(2):201-205.
8. Meyerson M. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511(7511):543-550.
9. Creighton CJ, et al. Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers. Cancer Res. 2010;70(5):1906-1915.
10. Greenberg E, et al. Regulation of cancer aggressive features in melanoma cells by microRNAs. PLoS One. 2011;6(4):e18936.
11. Guo J, et al. Differential expression of microRNA species in human gastric cancer versus non-tumorous tissues. J Gastroenterol Hepatol. 2009;24(4):652-657.
12. Kim HS, et al. MicroRNA-31 functions as a tumor suppressor by regulating cell cycle epithelialmesenchymal transition regulatory proteins in liver cancer. Oncotarget. 2015;6(10):8089-8102.
13. Laurila EM, Kallioniemi A. The diverse role of miR-31 in regulating cancer associated phenotypes. Genes Chromosomes Cancer. 2013;52(12):1103-1113.
14. Schaefer A, et al. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer. 2010;126(5):1166-1176.
15. Wszolek MF, et al. A MicroRNA expression profile defining the invasive bladder tumor phenotype. Urol Oncol. 2011;29(6):794-801 e1.
16. Yan LX, et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA. 2008;14(11):2348-2360.
17. Zhang T, et al. The oncogenetic role of microRNA-31 as a potential biomarker in oesophageal squamous cell carcinoma. Clin Sci (Lond). 2011;121(10):437-447.
18. Tan X, et al. A 5-microRNA signature for lung squamous cell carcinoma diagnosis and hsa-miR-31 for prognosis. Clin Cancer Res. 2011;17(21):6802-6811.
19. Slattery ML, et al. An evaluation replication of miRNAs with disease stage colorectal cancer-specific mortality. Int J Cancer. 2014;137(2):428-438.
20. Liu CJ, et al. miR-31 ablates expression of the HIF regulatory factor FIH to activate the HIF pathway in head and neck carcinoma. Cancer Res. 2010;70(4):1635-1644.
21. Liu X, et al. MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J Clin Invest. 2010;120(4):1298-1309.
22. Meng W, et al. MicroRNA-31 predicts the presence of lymph node metastases and survival in patients with lung adenocarcinoma. Clin Cancer Res. 2013;19(19):5423-5433.
23. Mahler JF, Stokes W, Mann PC, Takaoka M, Maronpot RR. Spontaneous lesions in aging FVB/N mice. Toxicol Pathol. 1996;24(6):710-716.
24. Westcott PM, et al. The mutational landscapes of genetic and chemical models of Kras-driven lung cancer. Nature. 2015;517(7535):489-492.
25. Mori I, et al. Aberrant expression of cyclin D1 in pulmonary proliferative lesions induced by high doses of urethane in transgenic mice carrying the human prototype c-H-ras gene. J Vet Med Sci. 2001;63(3):261-268.
26. Huang W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44-57.
27. Huang W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009;37(1):1-13.
28. Yang MH, et al. Elevated microRNA-31 expression regulates colorectal cancer progression by repressing its target gene SATB2. PLoS One. 2013;8(12):e85353.
29. Clark GJ, Westwick JK, Der CJ. p120 GAP modulates Ras activation of Jun kinases and transformation. J Biol Chem. 1997;272(3):1677-1681.
30. Bundschu K, Walter U, Schuh K. The VASPSpred-Sprouty domain puzzle. J Biol Chem. 2006;281(48):36477-36481.
31. Samatar AA, Poulikakos PI. Targeting RAS-ERK signalling in cancer: promises and challenges. Nat Rev Drug Discov. 2014;13(12):928-942.
32. Dankort D, Filenova E, Collado M, Serrano M, Jones K, McMahon M. A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev. 2007;21(4):379-384.
33. Saxena M, Christofori G. Rebuilding cancer metastasis in the mouse. Mol Oncol. 2013;7(2):283-296.
34. Wang S, et al. Down-regulated expression of SATB2 is associated with metastasis and poor prognosis in colorectal cancer. J Pathol. 2009;219(1):114-122.
35. Koumangoye RB, et al. SOX4 interacts with EZH2 and HDAC3 to suppress microRNA-31 in invasive esophageal cancer cells. Mol Cancer. 2015;14(1):24.
36. Zhang Q, Padi SK, Tindall DJ, Guo B. Polycomb protein EZH2 suppresses apoptosis by silencing the proapoptotic miR-31. Cell Death Dis. 2014;5:e1486.
37. Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov. 2010;9(10):775-789.
38. Ebert MS, Sharp PA. Roles for microRNAs in conferring robustness to biological processes. Cell. 2012;149(3):515-524.
39. Hu C, Huang F, Deng G, Nie W, Huang W, Zeng X. miR-31 promotes oncogenesis in intrahepatic cholangiocarcinoma cells via the direct suppression of RASA1. Exp Ther Med. 2013;6(5):1265-1270.
40. Sun D, et al. MicroRNA-31 activates the RAS pathway and functions as an oncogenic MicroRNA in human colorectal cancer by repressing RAS p21 GTPase activating protein 1 (RASA1). J Biol Chem. 2013;288(13):9508-9518.
41. Shaw AT, et al. Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis. Genes Dev. 2007;21(6):694-707.
42. Tennis MA, Van Scoyk MM, Freeman SV, Vandervest KM, Nemenoff RA, Winn RA. Sprouty-4 inhibits transformed cell growth, migration and invasion, and epithelial-mesenchymal transition, and is regulated by Wnt7A through PPARγ in non-small cell lung cancer. Mol Cancer Res. 2010;8(6):833-843.
43. Ledda F, Paratcha G. Negative regulation of Receptor Tyrosine Kinase (RTK) signaling: A developing field. Biomark Insights. 2007;2:45-58.
44. Sewing A, Wiseman B, Lloyd AC, Land H. Highintensity Raf signal causes cell cycle arrest mediated by p21Cip1. Mol Cell Biol. 1997;17(9):5588-5597.
45. Woods D, Parry D, Cherwinski H, Bosch E, Lees E, McMahon M. Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1. Mol Cell Biol. 1997;17(9):5598-5611.
46. MiRza AM, Gysin S, Malek N, Nakayama K, Roberts JM, McMahon M. Cooperative regulation of the cell division cycle by the protein kinases RAF and AKT. Mol Cell Biol. 2004;24(24):10868-10881.
47. Yamamoto T, Ebisuya M, Ashida F, Okamoto K, Yonehara S, Nishida E. Continuous ERK activation downregulates antiproliferative genes throughout G1 phase to allow cell-cycle progression. Curr Biol. 2006;16(12):1171-1182.
48. Grieb BC, et al. Oncogenic protein MTBP interacts with MYC to promote tumorigenesis. Cancer Res. 2014;74(13):3591-3602.
49. Tichelaar JW, Lu W, Whitsett JA. Conditional expression of fibroblast growth factor-7 in the developing and mature lung. J Biol Chem. 2000;275(16):11858-11864.
50. Fisher GH, et al. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev. 2001;15(24):3249-3262.
51. Alt JR, Bouska A, Fernandez MR, Cerny RL, Xiao H, Eischen CM. Mdm2 binds to Nbs1 at sites of DNA damage and regulates double strand break repair. J Biol Chem. 2005;280(19):18771-18781.
52. McGirt LY, Adams CM, Baerenwald DA, Zwerner JP, Zic JA, Eischen CM. miR-223 regulates cell growth and targets proto-oncogenes in mycosis fungoides/cutaneous T-cell lymphoma. J Invest Dermatol. 2014;134(4):1101-1107.